{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Covid-19",
      "SARS-CoV-2",
      "amantadine",
      "antiviral drugs"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33804989",
  "DateCompleted": {
    "Year": "2021",
    "Month": "04",
    "Day": "16"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "03",
        "Day": "24"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "539",
      "10.3390/v13040539"
    ],
    "Journal": {
      "ISSN": "1999-4915",
      "JournalIssue": {
        "Volume": "13",
        "Issue": "4",
        "PubDate": {
          "Year": "2021",
          "Month": "Mar",
          "Day": "24"
        }
      },
      "Title": "Viruses",
      "ISOAbbreviation": "Viruses"
    },
    "ArticleTitle": "Amantadine Inhibits SARS-CoV-2 In Vitro.",
    "Abstract": {
      "AbstractText": [
        "Since the SARS-CoV-2 pandemic started in late 2019, the search for protective vaccines and for drug treatments has become mandatory to fight the global health emergency. Travel restrictions, social distancing, and face masks are suitable counter measures, but may not bring the pandemic under control because people will inadvertently or at a certain degree of restriction severity or duration become incompliant with the regulations. Even if vaccines are approved, the need for antiviral agents against SARS-CoV-2 will persist. However, unequivocal evidence for efficacy against SARS-CoV-2 has not been demonstrated for any of the repurposed antiviral drugs so far. Amantadine was approved as an antiviral drug against influenza A, and antiviral activity against SARS-CoV-2 has been reasoned by analogy but without data. We tested the efficacy of amantadine in vitro in Vero E6 cells infected with SARS-CoV-2. Indeed, amantadine inhibited SARS-CoV-2 replication in two separate experiments with IC<sub>50</sub> concentrations between 83 and 119 \u00b5M. Although these IC<sub>50</sub> concentrations are above therapeutic amantadine levels after systemic administration, topical administration by inhalation or intranasal instillation may result in sufficient amantadine concentration in the airway epithelium without high systemic exposure. However, further studies in other models are needed to prove this hypothesis."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Merz Pharmaceuticals GmbH, 60318 Frankfurt, Germany."
          }
        ],
        "LastName": "Fink",
        "ForeName": "Klaus",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Robert-Koch-Institut, Zentrum f\u00fcr Biologische Gefahren und Spezielle Pathogene: Hochpathogene Viren (ZBS 1), 13353 Berlin, Germany."
          }
        ],
        "LastName": "Nitsche",
        "ForeName": "Andreas",
        "Initials": "A"
      },
      {
        "Identifier": [
          "0000-0002-9430-5766"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Robert-Koch-Institut, Zentrum f\u00fcr Biologische Gefahren und Spezielle Pathogene: Hochpathogene Viren (ZBS 1), 13353 Berlin, Germany."
          }
        ],
        "LastName": "Neumann",
        "ForeName": "Markus",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Robert-Koch-Institut, Zentrum f\u00fcr Biologische Gefahren und Spezielle Pathogene: Hochpathogene Viren (ZBS 1), 13353 Berlin, Germany."
          }
        ],
        "LastName": "Grossegesse",
        "ForeName": "Marica",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Merz Pharmaceuticals GmbH, 60318 Frankfurt, Germany."
          }
        ],
        "LastName": "Eisele",
        "ForeName": "Karl-Heinz",
        "Initials": "KH"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Merz Pharmaceuticals GmbH, 60318 Frankfurt, Germany."
          }
        ],
        "LastName": "Danysz",
        "ForeName": "Wojciech",
        "Initials": "W"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Viruses",
    "NlmUniqueID": "101509722",
    "ISSNLinking": "1999-4915"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "BF4C9Z1J53",
      "NameOfSubstance": "Amantadine"
    }
  ],
  "CommentsCorrectionsList": [
    {
      "RefSource": "Viruses. 2022 Feb 28;14(3):",
      "PMID": "35336901"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Amantadine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Chlorocebus aethiops"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug effects",
        "genetics",
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Vero Cells"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Virus Replication"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ],
  "CoiStatement": "The authors A.N., M.N., and M.G. declare no conflict of interest. K.F., K.-H.E., and W.D. are employees of Merz Pharmaceuticals GmbH. Merz is original manufacturer of PK-Merz (amantadine)."
}